drugset / Trial / NCT00781482
Positron Emission Tomography Assessment of the Central Nervous System Effects of Eszopiclone and Zolpidem
Phase 4
Withdrawn
Kettering Health Network
Abiant, Inc. · collabSumitomo Pharma America, Inc. · collab
RandomizedCrossoverQuadruple-blindBasic science
Summary
This study will compare the interactions of a placebo and two FDA-approved sleeping medications, Eszopiclone (Lunesta) and Zolpidem (Ambien), with certain chemical receptors in the brain. We want to show that we can use positron emission tomography images to measure the binding of these medications to the receptors.
Timeline
- Start
- —
- Primary completion
- —
- Completion
- —
Outcome
Outcome not reported
Stopped: “Sponsor elected not to conduct study at this time.”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Eszopiclone | Small molecule | 3 mg | — |
| Subject | Zolpidem | Small molecule | 10 mg | — |
Indications
No indication recorded.